Publications by authors named "Jason Legg"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

11,339

Total Likes

508

Extended Reach

622,457

Social Features

162
T
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF).
Tor Biering-Sørensen, Masatoshi Minamisawa, Jiankang Liu, Brian Claggett, Alexander I Papolos, Jason C Legg

Eur J Heart Fail· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Jason C Legg

Eur J Heart Fail· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: Rationale and Design of GALACTIC-HF.
John R Teerlink, Rafael Diaz, G Michael Felker, John J V McMurray, Marco Metra, Jason C Legg

JACC Heart Fail· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Considerations in testing treatment effects on transient event driven health status changes measured by patient reported outcomes.
Jingyuan Liu, Jason C Legg, May Mo, Xuwen Zhang

Stat Med· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of LDL-C Reduction Using Different Evolocumab Doses and Intervals: Biological Insights and Treatment Implications.
Scott M Wasserman, Marc S Sabatine, Michael J Koren, Robert P Giugliano, Jason C Legg

J Cardiovasc Pharmacol Ther· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting.
Ricardo Dent, Raju Joshi, C Stephen Djedjos, Jason Legg, Mary Elliott

Springerplus· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?
Gary H Lyman, David C Dale, Jason C Legg, Esteban Abella, Phuong Khanh Morrow

Cancer Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Marc S Sabatine, Robert P Giugliano, Stephen D Wiviott, Frederick J Raal, Dirk J Blom, Jason Legg

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
Derek Weycker, Richard Barron, Alex Kartashov, Jason Legg, Gary H Lyman

J Oncol Pharm Pract· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discrete choice experiment to estimate breast cancer patients' preferences and willingness to pay for prophylactic granulocyte colony-stimulating factors.
Phaedra Johnson, Tim Bancroft, Richard Barron, Jason Legg, Xiaoyan Li

Value Health· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Jennifer G Robinson, Bettina S Nedergaard, William J Rogers, Jonathan Fialkow, Joel M Neutel, Jason C Legg

JAMA· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of LAPLACE-2: a phase 3, randomized, double-blind, placebo- and ezetimibe-controlled trial evaluating the efficacy and safety of evolocumab in subjects with hypercholesterolemia on background statin therapy.
Jennifer G Robinson, William J Rogers, Bettina S Nedergaard, Jonathan Fialkow, Joel M Neutel, Jason C Legg

Clin Cardiol· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis.
Derek Weycker, Rich Barron, John Edelsberg, Alex Kartashov, Jason Legg

BMC Health Serv Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia.
Brian Dulisse, Xiaoyan Li, Julie A Gayle, Richard L Barron, Frank R Ernst, Jason C Legg

J Med Econ· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Staff time and motion assessment for administration of erythropoiesis-stimulating agents: a two-phase pilot study in clinical oncology practices.
John F Reitan, Arletta van Breda, Patricia K Corey-Lisle, Sanatan Shreay, Ze Cong, Jason Legg

Clin Drug Investig· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent.
Robert Pirker, Melissa Pirolli, Jane Quigley, Scott Hulnick, Jason Legg

Support Care Cancer· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.
Derek Weycker, Oleg Sofrygin, Kim Seefeld, Robert G Deeter, Jason Legg

BMC Health Serv Res· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of electronic medical records (EMR) for oncology outcomes research: assessing the comparability of EMR information to patient registry and health claims data.
Edmund C Lau, Fionna S Mowat, Michael A Kelsh, Jason C Legg, Nicole M Engel-Nitz

Clin Epidemiol· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transfusion risk in cancer patients with chemotherapy-induced anemia when initiating darbepoetin alfa therapy at a baseline hemoglobin level of <9 g/dL versus 9 to <10 g/dL versus ≥ 10 g/dL: an exploratory analysis of a phase 3 trial.
Jean-Luc Canon, Johan Vansteenkiste, Michael Hedenus, Pere Gascon, Carsten Bokemeyer, Jason Legg

Med Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of bleeding-related episodes in patients with immune thrombocytopenia (ITP) receiving romiplostim or medical standard of care.
Roberto Stasi, Magaral Murali, Marc Michel, Jean-François Viallard, Aristoteles Giagounidis, Jason Legg

Int J Hematol· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in neutropenia-related inpatient events.
Chris M Kozma, Michael Dickson, Victoria Chia, Jason Legg, Richard Barron

J Oncol Pract· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
Robert I Griffiths, Richard L Barron, Michelle L Gleeson, Mark D Danese, Anthony O'Hagan, Jason C Legg

Pharmacoeconomics· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
Donald E Stull, Margaret K Vernon, Jason C Legg, Hema N Viswanathan, Diane Fairclough

Contemp Clin Trials· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis